DNER and neoplasm: ABBV-075 (48), a selective BET inhibitor developed by AbbVie, has progressed to phase I clinical trials and demonstrated superior anti-tumor activity in solid tumors and hematological malignancies through multiple mechanisms, including blocking G1 phase, promoting apoptosis, and disrupting the tumor micro-environment [84].